Showing 4361-4370 of 5957 results for "".
- Opus Genetics Acquires Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases from Iveric Biohttps://modernod.com/news/opus-genetics-acquires-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/2481311/Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1(BEST1)-related inherited retinal diseases a
- Study Identifies a Signaling Cascade Behind Retina Regeneration in Zebrafishhttps://modernod.com/news/study-identifies-a-signaling-cascade-behind-retina-regeneration-in-zebrafish/2481309/Experts at University of Michigan Medical School are investigating how Muller glial cells, responsible for regenerating a damaged zebrafish retina, acquire stem cell properties with the hope of eventually developing techniques to encourage human retinas to regenerate. Building
- Outlook Therapeutics Announces Validation of Marketing Authorization Application by the EMA for ONS-5010 for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd/2481308/Outlook Therapeutics announced the validation of its marketing authorization application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degener
- Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Studyhttps://modernod.com/news/melt-pharmaceuticals-melt-300-achieves-primary-sedation-endpoint-in-phase-2-pivotal-efficacy-and-safety-study/2481307/Melt Pharmaceuticals announced topline results of its phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the
- Iveric Bio Completes Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-completion-of-rolling-nda-submission-to-fda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481305/Iveric Bio announced that it has submitted to the FDA the third and final part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.
- New Genetic Mutation Behind Childhood Glaucoma Identifiedhttps://modernod.com/news/new-genetic-mutation-behind-childhood-glaucoma-identified/2481303/An international team led by Harvard Medical School scientists at Mass Eye and Ear and Boston Children’s Hospital has discovered a new genetic mutation that may be a root cause of severe cases of childhood glaucoma, according to a Harvard Medical School research
- Staar Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEOhttps://modernod.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/Staar Surgical announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after serving in that postion for 7 years. Staar's Board of Directors has appointed ophthalmic industry executive Thomas G. Frinzi, current Board Chair of Staar,
- Parexel Enters Agreement with MyEyeDr to Refer Patients into Existing and Future Ophthalmology Clinical Trialshttps://modernod.com/news/parexel-enters-agreement-with-myeyedr-to-refer-patients-into-existing-and-future-ophthalmology-clinical-trials/2481298/Parexel, a clinical research organization (CRO), announced a formal agreement with MyEyeDr to refer its patients into existing and future ophthalmology clinical trials. Terms of the deal were not disclosed. Parexel and MyEyeDr are currently collaborating on recruitme
- AI-Diagnostics Startup Altris AI Raises $1 Million to Scale AI-Based Eye Care Diagnostics Platformhttps://modernod.com/news/ai-diagnostics-startup-altris-ai-raises-1-million/2481296/Altris AI announced it has raised $1 million to scale its AI-enabled eye care diagnostics solution. Altris AI, which is a US-based startup originally from Ukraine, developed a SaaS platform based on 5 million OCT scans that detected and interpreted more than 100 pathologies an